Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.51 |
| ▸ | KIT | P10721 | 5/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 3/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038050 | 1.00 | FLT3 (0.51) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL4036467 | 0.92 | FLT3 (0.53) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL4036472 | 0.92 | FLT3 (0.53) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL4042249 | 0.87 | FLT3 (0.54) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL4042254 | 0.87 | FLT3 (0.54) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL4046134 | 0.82 | FLT3 (0.52) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL12845295 | 0.82 | FLT3 (0.55) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL12780406 | 0.82 | FLT3 (0.61) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL4043796 | 0.80 | FLT3 (0.61) | FLT3KITIRAK4JAK2AURKA | |
| SCHEMBL12780409 | 0.80 | FLT3 (0.57) | FLT3KITIRAK4JAK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885KIT 1144/4885IRAK4 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.